MX2023002413A - Proteinas de fusion inmunogenicas de coronavirus y metodos relacionados. - Google Patents
Proteinas de fusion inmunogenicas de coronavirus y metodos relacionados.Info
- Publication number
- MX2023002413A MX2023002413A MX2023002413A MX2023002413A MX2023002413A MX 2023002413 A MX2023002413 A MX 2023002413A MX 2023002413 A MX2023002413 A MX 2023002413A MX 2023002413 A MX2023002413 A MX 2023002413A MX 2023002413 A MX2023002413 A MX 2023002413A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- coronavirus
- immunogenic
- related methods
- vectors
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 241000711573 Coronaviridae Species 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000013598 vector Substances 0.000 abstract 3
- 229940096437 Protein S Drugs 0.000 abstract 2
- 101710198474 Spike protein Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000002105 nanoparticle Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 101710157275 Ferritin subunit Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000013638 trimer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan proteínas de fusión que incluyen una secuencia de aminoácidos de un ectodominio de la proteína Espiga de un coronavirus, tal como el SARS-CoV-2, unida a una secuencia de aminoácidos de un polipéptido de subunidad de ferritina. También se proporcionan nanopartículas que incluyen tales proteínas de fusión, con trímeros expuestos en superficie del ectodominio de la proteína Espiga del coronavirus. También se proporcionan ácidos nucleicos y vectores que codifican las proteínas de fusión, células que contienen dicho ácido nucleico y vectores, composiciones inmunogénicas que incluyen las proteínas de fusión, las nanopartículas o los vectores, así como los métodos y kits correspondientes.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063070961P | 2020-08-27 | 2020-08-27 | |
US202063130056P | 2020-12-23 | 2020-12-23 | |
US202163196837P | 2021-06-04 | 2021-06-04 | |
PCT/US2021/047885 WO2022047116A1 (en) | 2020-08-27 | 2021-08-27 | Immunogenic coronavirus fusion proteins and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023002413A true MX2023002413A (es) | 2023-05-23 |
Family
ID=80354081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023002413A MX2023002413A (es) | 2020-08-27 | 2021-08-27 | Proteinas de fusion inmunogenicas de coronavirus y metodos relacionados. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230399364A1 (es) |
EP (1) | EP4203998A1 (es) |
JP (1) | JP2023540486A (es) |
KR (1) | KR20230084478A (es) |
AU (1) | AU2021333793A1 (es) |
BR (1) | BR112023003526A2 (es) |
CA (1) | CA3193288A1 (es) |
CL (1) | CL2023000566A1 (es) |
CO (1) | CO2023003453A2 (es) |
IL (1) | IL300905A (es) |
MX (1) | MX2023002413A (es) |
WO (1) | WO2022047116A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114717205A (zh) * | 2022-03-29 | 2022-07-08 | 中国人民解放军军事科学院军事医学研究院 | 一种冠状病毒RBDdm变异体及其应用 |
WO2024059149A2 (en) * | 2022-09-14 | 2024-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Immunogenic coronavirus fusion proteins and related methods |
CN115746148B (zh) * | 2022-10-14 | 2023-09-12 | 中国医学科学院病原生物学研究所 | 具有冠状病毒rbd和膜融合抑制多肽的蛋白质及其作为冠状病毒抑制剂的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4463481B2 (ja) * | 2001-05-17 | 2010-05-19 | ウニフェルシテイト ユトレヒト | 機能的に欠失したゲノムを含むコロナウイルス様の粒子 |
US9441019B2 (en) * | 2011-09-23 | 2016-09-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Influenza hemagglutinin protein-based vaccines |
-
2021
- 2021-08-27 WO PCT/US2021/047885 patent/WO2022047116A1/en active Application Filing
- 2021-08-27 MX MX2023002413A patent/MX2023002413A/es unknown
- 2021-08-27 CA CA3193288A patent/CA3193288A1/en active Pending
- 2021-08-27 KR KR1020237010064A patent/KR20230084478A/ko unknown
- 2021-08-27 BR BR112023003526A patent/BR112023003526A2/pt unknown
- 2021-08-27 IL IL300905A patent/IL300905A/en unknown
- 2021-08-27 US US18/043,285 patent/US20230399364A1/en active Pending
- 2021-08-27 EP EP21862795.8A patent/EP4203998A1/en active Pending
- 2021-08-27 AU AU2021333793A patent/AU2021333793A1/en active Pending
- 2021-08-27 JP JP2023513740A patent/JP2023540486A/ja active Pending
-
2023
- 2023-02-27 CL CL2023000566A patent/CL2023000566A1/es unknown
- 2023-03-21 CO CONC2023/0003453A patent/CO2023003453A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2023000566A1 (es) | 2023-10-30 |
BR112023003526A2 (pt) | 2023-04-11 |
US20230399364A1 (en) | 2023-12-14 |
KR20230084478A (ko) | 2023-06-13 |
CO2023003453A2 (es) | 2023-04-27 |
CA3193288A1 (en) | 2022-03-03 |
JP2023540486A (ja) | 2023-09-25 |
EP4203998A1 (en) | 2023-07-05 |
WO2022047116A1 (en) | 2022-03-03 |
AU2021333793A1 (en) | 2023-04-13 |
IL300905A (en) | 2023-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023002413A (es) | Proteinas de fusion inmunogenicas de coronavirus y metodos relacionados. | |
MX2023003255A (es) | Polipeptidos efectores crispr-cas y metodos para su uso. | |
AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
JP2015531407A5 (es) | ||
TW200732472A (en) | Method for the recombinant expression of a polypeptide | |
AR047345A1 (es) | Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes | |
CN105061581A (zh) | 可基因编码的全蛋白质索烃的制备方法 | |
WO2007149491A3 (en) | Soluble stabilized trimeric hiv env proteins and uses thereof | |
PH12017502080A1 (en) | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same | |
WO2021198706A3 (en) | Coronavirus vaccines | |
WO2016130628A8 (en) | Griffithsin mutants | |
MX2022007858A (es) | Polipeptidos efectores crispr-cas y metodos de uso de estos. | |
JP2015517464A5 (es) | ||
WO2021207517A3 (en) | Modified hr2 peptide inhibitors of coronavirus fusion | |
DE602007011616D1 (de) | Verfahren zur herstellung von oligopeptiden | |
IL157766A0 (en) | Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses | |
WO2004022697A3 (en) | Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof | |
WO2024059149A3 (en) | Immunogenic coronavirus fusion proteins and related methods | |
EA202092065A1 (ru) | ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA) | |
WO2011142529A3 (en) | Soluble expression of bulky folded active proteins | |
MX2022004410A (es) | Polipeptidos recombinantes para localizacion celular regulable. | |
WO2019046446A3 (en) | COMPOSITIONS AND METHODS USING METHANOTROPHE LAYER PROTEINS FOR THE EXPRESSION OF HETEROLOGOUS PROTEINS | |
EP1570051A4 (en) | HYBRID GENES AND COMPOSITIONS COMPRISING RRE AND CTE AND USES THEREOF | |
DE60033583D1 (de) | Eine mycobacterium tuberculosis kodierende sequenz zur expression von heterologen proteinen | |
WO2004056316A3 (en) | Vaccines against hiv-1 tat protein to generate neutralizing antibodies |